Recombinant human fibronectin fragment (FN-CH296, RetroNectin) has been widely used for retroviral gene therapy to enhance gene transfer efficiency. Based on the observation that immobilized FN-CH296 together with anti-CD3 monoclonal antibodies (anti-CD3) enhanced cell proliferation while conserving the naive phenotype of T cells, we used FN-CH296 costimulation to generate engineered T cells. For comparison, human peripheral blood mononuclear cells were stimulated under three kinds of conditions including anti-CD3 only, anti-CD3 and anti-CD28 monoclonal antibodies conjugated with beads (anti-CD3/anti-CD28) and immobilized FN-CH296 together with anti-CD3 (anti-CD3/FN-CH296); all three treatments were followed by retroviral gene transfer. Of all the stimulation methods, the one involving anti-CD3/FN-CH296 produced the most cell expansion with conservation of the naive phenotype. Engineered T cells were transplanted into NOD/SCID (non-obese diabetic/severe combined immunodeficient) mice, and all the mice were killed 14 days later. Transplanted T cells were detected in all the mice; however, mice injected with anti-CD3/FN-CH296-stimulated T cells showed higher transgene expression in organs than mice injected with anti-CD3-stimulated cells. These results demonstrate that the anti-CD3/FN-CH296 stimulation can be an efficient way to generate large numbers of genetically modified T cells that can provide higher and longer lasting levels of transgene expression in vivo and that are suitable for adoptive T-cell transfer therapy.
Introduction
Adoptive T-cell (ATC) transfer therapy, the infusion of tumor-reactive T cells into patients, is a promising approach for the treatment of metastatic diseases (for a review, see June 1 ). Early attempts at ATC therapies have achieved T-cell stimulation ex vivo by activating and expanding autologous tumor-infiltrating lymphocytes to large numbers, which are then transferred back into the patient; these attempts have met with some success. 2, 3 However, owing to difficulties in isolating tumor-specific T cells in sufficient quantities, an alternative approach was devised to transfer into cytotoxic T cells either T-cell receptor (TCR) genes isolated from high-affinity cytotoxic T lymphocytes or recombinant chimeric TCR genes, the antigen-binding domain of which was derived from an antibody against tumor antigen.
4,5 Expression of these types of TCR in immunological effector cells should produce tumor-specific T cells capable of mounting an antitumor effect in vivo. Unfortunately, until recently, therapeutic effects have been reported in only a handful of cases. 6 Mouse studies and clinical trials indicate that the differentiation state of the adoptively transferred T-cell populations is crucial to the success of T-cell-based approaches (for a review, see Gattinoni et al. 7 ). Mouse models have shown that naive and early effector T cells mediate stronger in vivo antitumor responses than intermediate and late effector T cells. 8 In humans, mounting evidence seems to support the preclinical finding that less-differentiated T cells are ideal for ATC transfer therapy. [9] [10] [11] Thus, obtaining naive or lessdifferentiated CD8 þ T cells that are specific for tumor antigen may be of paramount importance for improving current T-cell-based therapies, thereby reconstituting a long-lasting immune system in patients.
Fibronectin (FN), one of the major extracellular matrix proteins, is a disulfide-linked dimeric glycoprotein containing several functional domains with cell-binding properties. [12] [13] [14] A number of studies have shown that FN functions not only as an adhesion molecule but also as a signal inducer via its binding to integrins expressed on T cells. FN acts together with anti-CD3 to induce T-cell proliferation, which is thought to depend on integrin very late activation antigen-4 (VLA-4)/CS1 interactions. [15] [16] [17] We previously showed that FN-CH296, a recombinant fragment of human FN, 18 could stimulate peripheral blood T-cell growth in vitro when used together with anti-CD3. 19, 20 In addition, anti-CD3/ FN-CH296-stimulated T cells contained more naive T cells than T cells stimulated by other methods. The Rosenberg group has shown that naive phenotype cells are more active in mediating tumor regression than cells with a more differentiated phenotype. 8 This finding led us to apply FN-CH296-mediated stimulation to naive phenotype T cells to generate 'fit T cells,' 7, 8 which are ideal for ATC transfer.
In this study, we investigated whether T lymphocytes stimulated with anti-CD3/FN-CH296 were suitable for ATC transfer. Compared to other available T-cell stimulation procedures, using FN-CH296 stimulation generated higher numbers of genetically modified T cells with a naive phenotype and homing receptors. The genetically modified T cells were prepared on a large scale and were efficiently grafted into NOD/SCID (nonobese diabetic/severe combined immunodeficient) mice. All of the injected mice expressed the transgene at high levels until 14 days after transplantation. Large numbers of the transduced human cells were observed in peripheral blood and in several organs. Our novel ex vivo T-cell expansion method, utilizing FN-CH296 stimulation, could be an efficient way for preparing large numbers of genetically modified T cells for ATC transfer therapy.
Materials and methods

Retroviral vectors and viral production
The retroviral vector backbone used in this study, pMT, has been previously described. 21, 22 MT-AcGFP was constructed by inserting the AcGFP gene amplified from pIRES2-AcGFP1 (Clontech, Mountain View, CA) using primers as follows: AcGFP5, acgcgtagatctatggtgagcaag ggcgcc; AcGFP3, ggatcctcacttgtacagctc.
Generation of PG13-packaging cell clones was initiated by transducing ecotropic MT-AcGFP virus produced from 293T cells. 293T cells were first transfected with MT-AcGFP plasmid along with pCA-GP and pE-Eco packaging plasmids (Takara Bio, Otsu, Japan) using TransIT-293 reagent (Mirus, Madison, WI). Cell-free viral supernatants obtained from 293T cells were then used to transduce PG13 cells. Transduced PG13 cell clones were obtained by limiting dilution and expanded. The high-titer clones were selected by measuring viral genome copies from culture supernatant using the real-time PCR method. 22 Stimulation and transduction of peripheral blood lymphocytes Peripheral blood samples were obtained from healthy volunteers who had given their informed consent. Mononuclear cells were isolated using Cytomate (Baxter, Deerfield, IL) and frozen until use. The recovered peripheral blood mononuclear cells (PBMCs) were resuspended at a concentration of 0.3 Â 10 6 cells ml À1 in serum-free media, GT-T503 (Takara Bio), supplemented with 1% plasma, 0.2% human serum albumin (HSA) (Baxter) and 600 IU ml À1 interleukin (IL)-2 (Chiron, Emeryville, CA). For stimulation, PBMCs were seeded in a six-well plate and stimulated with anti-CD3 (30 ng ml
À1
; Janssen Pharmaceutica, Tokyo, Japan), paramagnetic anti-CD3/anti-CD28 (1:1 beads/T cell; Invitrogen, Carlsbad, CA) or anti-CD3/FN-CH296. For anti-CD3/FN-CH296 stimulation, a six-well plate that was precoated with FN-CH296 (RetroNectin, 30 mg per well; Takara Bio) and anti-CD3 (6 mg per well) was used. At days 3 and 4, cells were transduced with the retroviral vectors using the viral preloading method. Briefly, FN-CH296-coated six-well plates were loaded with a retroviral vector supernatant, and centrifuged at 1000 g for 2 h at 32 1C, followed by incubation at 37 1C for 2 h. The plates were then washed with phosphate-buffered saline, and stimulated cells were added at 0.5 Â 10 6 cells ml À1 (2 ml per well). The cells were incubated for 4 h at 37 1C, added to 8 ml of media, transferred to a new six-well plate and incubated overnight. The procedure was repeated the following day. At day 4, transduced cells were harvested after 4 h incubation on viral-coated plates and resuspended at a concentration of 0.2 Â 10 6 cells ml À1 in culture media. They were then maintained until day 7 or 10 without further stimulation.
Fluorescence-activated cell sorter analysis Flow cytometry was used for the analysis of surface phenotype and transduction efficiency. The following monoclonal antibodies were used: PE-(BD Biosciences, Franklin Lakes, NJ) or ECD-conjugated anti-CD4 (Beckman Coulter, Fullerton, CA), PE-(BD Biosciences) or Tri-color-conjugated anti-CD8 (Invitrogen), PE-conjugated anti-CCR7 (R&D Systems, Franklin Lakes, NJ), ECD-conjugated anti-CD45RA (Beckman Coulter), PEconjugated anti-CD62L (BD Biosciences), PC5-conjugated anti-CD27 (Beckman Coulter) and PE-conjugated anti-CD28 (eBioscience, San Diego, CA). Samples were run through a FACSCalibur flow cytometer (BD Biosciences) after isotype-matched fluorochrome-conjugated irrelevant monoclonal antibody-stained control, and data were analyzed using CellQuest software (BD Biosciences). The presence of human or mouse cells in blood, spleen, thymus and marrow samples was assessed by flow cytometric analysis, using PC5-conjugated antihuman CD3 antibody (Beckman Coulter) and PE-conjugated anti-mouse CD45 (Beckman Coulter), respectively.
Upscale production and transduction of PBMCs For the preparation of anti-CD3 or anti-CD3/anti-CD28 stimulation, frozen PBMCs were resuspended in culture medium (GT-T503 supplemented with 1% plasma, 0.2% HSA and 600 IU ml À1 IL-2), seeded in CultiLife Eva bags (Takara Bio) at 0. . At days 3 and 4, cells were harvested and transduced with the MT-AcGFP vector. Briefly, for preloading of virus, 30 ml of viral supernatant was seeded in a CultiLife Spin bag (Takara Bio) precoated with FN-CH296, and the bag was centrifuged at 2000 g for 2 h at 32 1C. After centrifugation, the viral solution was removed and washed with phosphate-buffered saline containing 1.5% HSA. Then, harvested PBMCs were resuspended in culture media and seeded in a CultiLife Spin bag at 1-2 Â 10 6 cells cm
À2
. The bags were then centrifuged again at 1000 g for 10 min at 32 1C followed by incubation for 4 h at 37 1C. After incubation, transduced PBMCs were harvested, resuspended in culture media and seeded in CultiLife Eva bags at 0.5 Â 10 6 cells ml
À1
. At day 4, the same procedure was repeated, and transduced cells were resuspended in culture media, seeded in CultiLife Eva bags at 0.2 Â 10 6 cells ml À1 and incubated until day 8.
Transplantation to NOD/SCID mice Four-week-old female NOD/ShiJic-scid (NOD/SCID) mice were obtained from CLEA Japan (Tokyo, Japan) and maintained under specific pathogen-free conditions until 8 weeks of age. On the day before transplantation, mice were intraperitoneally given 20 ml anti-asialo GM1 antiserum (Wako, Osaka, Japan) in 300 ml normal saline solution containing 0.4% HSA to remove residual natural killer activity. At day 0, mice received total body irradiation with a single dose of 350 cGy and were immediately infused with unmodified PBMCs or transduced PBMCs. A 2 Â 10 4 IU portion of hIL-2 was injected in all mice intraperitoneally at days 0-2, and 3.3 Â 10 7 cells were resuspended in 300 ml normal saline solution containing 4% HSA and infused intravenously. Mice were then monitored and killed at day 14. Engraftment efficiency was calculated as follows:
Histology and immunohistochemistry Postmortem collections of organs included spleen, bone marrow, thymus, gut and liver. For immunohisto chemistry, organs were embedded in tissue-freezing medium and stored at À80 1C until usage. Tissue sections (5 mm) were cut in a cryostat and stained with hematoxylin and eosin for morphologic evaluation. The presence of human T lymphocytes was analyzed by counterstaining with human monoclonal anti-CD3 antibodies and peroxidaseconjugated second-step reagent.
Results
T-cell stimulation for retroviral transduction
To investigate whether the stimulation of T cells with anti-CD3/FN-CH296 followed by retroviral gene transfer is useful for preparing T cells for ATC transfer therapy, we compared this stimulation method with other methods currently available, including stimulation with anti-CD3 only and with anti-CD3/anti-CD28. Frozen PBMCs obtained from healthy donors were recovered, stimulated by each method for 3 days and transduced with retroviral vectors (Figure 1a ). For this experiment, retroviral vector MT-AcGFP expressing AcGFP only was used (Figure 1b) . The retroviral transduction was performed twice at days 3 and 4 after initiation of culture, using FN-CH296-coated plates preloaded with retroviral vectors. Transduced populations were further cultured in maintenance media until day 10 after initiation of culture ( Figure 1a) . The experiments were performed in triplicate using PBMCs from three different donors, and one representative result was presented. The viable cell numbers, as determined by Trypan blue exclusion, showed a dramatic increase under all conditions starting on day 4 ( Figure 1c ). Among the three kinds of culture conditions, however, PBMCs stimulated with anti-CD3/ FN-CH296 showed the highest cell growth: this cell population expanded 44-fold in the 7-day culture period, compared to 8-fold for anti-CD3 stimulation and 33-fold for anti-CD3/anti-CD28 stimulation. We usually observed 4100-200-fold expansion after 10 days in culture. Therefore, the growth of anti-CD3/FN-CH296-stimulated cells was 45-fold higher than that seen with cells stimulated by anti-CD3 alone, and it was quite comparable with, or even slightly higher than, the growth seen with anti-CD3/anti-CD28-stimulated cells. Untransduced cells also showed similar cell growth patterns, implying that the transduction process did not significantly impair cell growth (data not shown). The gene transfer efficiency was measured by AcGFP expression on day 7. As shown in Figure 1d , transductions mediated by retroviral vectors were highly efficient under all three stimulation conditions, reaching more than 70% after two transduction rounds. These results suggest that the anti-CD3/FN-CH296 stimulation method could be beneficial to gene therapy of T cells because it provides enhanced cell growth and efficient gene transfer.
Phenotype of transduced populations
Changes in cell-surface phenotype during stimulation, transduction and culture were analyzed. Cells stimulated with anti-CD3 or anti-CD3/FN-CH296 showed similar patterns for CD4 and CD8 subpopulations; without stimulation, the recovered PBMCs contained approximately 45% CD4 þ cells and 30% CD8 þ cells. However, on day 7, the CD8 þ population increased to almost 60%, whereas the CD4 þ population decreased (Figure 2a) . In contrast, anti-CD3/anti-CD28-stimulated PBMCs showed a quite different pattern. CD4 þ populations were slightly increased, meaning that the cultured cells contained a higher proportion of CD4 þ T cells than the populations stimulated in other ways. The CD4 þ /CD8 þ ratio did not change when green fluorescent protein þ (GFP þ ) cells were gated and analyzed, suggesting that the efficiency of retroviral infection was similar for both populations (data not shown).
To assess the status of T-cell differentiation in transduced T cells, transduced PBMCs were analyzed by flow cytometry for CD45RA and CCR7 expression. Before stimulation, recovered PBMCs contained 48% of cells having a CD45RA þ /CCR7 þ naive phenotype (Figure 2b ). After stimulation and transduction, cells with a naive phenotype were decreased to differing degrees in populations stimulated with anti-CD3 and anti-CD3/anti-CD28 by day 7 (Figure 2b) . In contrast, the number of CD45RA þ /CCR7 þ cells did not change significantly in the population stimulated with anti-CD3/ FN-CH296, and it remained at a level similar to that seen in unstimulated PBMCs (Figure 2b ). When GFP þ cells were gated and analyzed, similar results were obtained; anti-CD3/FN-CH296-stimulated PBMCs contained a considerably higher proportion of naive phenotype cells expressing the transgene than the proportion produced after other types of stimulation (Figure 2c ). These results demonstrate that T lymphocytes with a naive phenotype are well preserved and efficiently transduced with retroviral vector when stimulated by anti-CD3/FN-CH296. These higher numbers of transduced cells with a naive phenotype should translate to longer persistence of transduced T cells in vivo because of their high proliferative potential.
It has been shown that CD8 þ T cells that can home in on secondary lymph nodes, where they can be effectively stimulated by dendritic cells, are more effective in adoptive immunotherapy. 8, 23, 24 Thus, the expression level of lymphoid homing molecule CD62L in transduced T cells might be another important factor affecting successful ATC transfer therapy. As anti-CD3/FN-CH296-stimulated PBMCs contained higher numbers of less differentiated cells, a high proportion of GFP þ cells were found to be CD62L þ /CD8 þ (47%), whereas transduced cells stimulated in other ways contained lower numbers of CD62L þ /CD8 þ cells (Figure 2d ). It remains to be investigated whether anti-CD3/FN-CH296-stimulated PBMCs expressing high levels of lymphoid homing molecule are more efficient at targeting and inhibiting tumor growth compared with PBMCs stimulated by other methods in which CD62L expression is downregulated.
Scaled-up production of anti-CD3/FN-CH296-stimulated cells To examine engraftment and in vivo persistence of genetically modified T cells stimulated with anti-CD3/ FN-CH296, PBMCs were stimulated and transduced on a large scale for NOD/SCID transplantation. Transduced PBMCs were produced by using the closed culture bag system, and the results are summarized in Table 1 . Three kinds of gas-permeable bags were used for each step (PBMC stimulation, transduction and culture), as described in Materials and methods. Briefly, the gas-permeable bag that was precoated with FN-CH296 and anti-CD3 
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was used for stimulation, and another bag precoated with FN-CH296 alone was used for transduction. Transduction was performed twice at days 3 and 4 after initiation of culture, and transduced cells were further cultured without FN-CH296. Frozen PBMCs (1.3 Â 10 8 cells) were recovered and proliferated 52-fold during 8 days in culture. As a control, we also scaled up the production of cells stimulated with anti-CD3 and anti-CD3/ anti-CD28. In these cases, 1.9 Â 10 8 of frozen PBMCs were recovered and seeded in bags containing anti-CD3 or paramagnetic anti-CD3/anti-CD28 antibody beads for stimulation. Using the method described above, the anti-CD3-and anti-CD3/anti-CD28-stimulated populations grew in number by 30-and 44-fold, respectively, after 8 days in culture. On the day of harvest (day 8), more than 75% of PBMCs expressed AcGFP under all three conditions. There was no significant difference in CD4 þ /CD8 þ ratios between cells stimulated by anti-CD3 or anti-CD3/FN-CH296. However, anti-CD3/ anti-CD28-stimulated cells contained higher numbers of CD4 þ cells than other stimulated cells, consistent with the above observation ( Figure 2 and Table 1 ). The differentiation status of transduced cells further confirmed the above observation. Anti-CD3/FN-CH296-stimulated PBMCs contained higher numbers of cells with CD45RA þ /CCR7 þ naive phenotype than cells stimulated by other methods, whereas anti-CD3/anti-CD28-stimulated PBMCs contained higher numbers of CD45RAÀ/CCR7 þ central memory (CM) cells than other samples (Figure 2 and Table 1 ). In addition to CD45RA and CCR7, we also measured other surface markers including CD62L and CD27, which have been Figure 1) .
Transplantation to NOD/SCID mice Transduced cells were transplanted into the sublethally irradiated NOD/SCID mice at 3 Â 10 7 cells per mouse. The first bleeding was done 7 days after infusion, and the blood sample was used to analyze the engraftment efficiency and AcGFP expression. As shown in Table 2 , engraftments were extremely efficient for all groups. The engraftment efficiency measured by the ratio of human to mouse cells in mouse blood averaged 490% in all groups ( Table 2 ). Administration of hIL-2 to mice after transplantation seemed to contribute to this efficient implantation. Transplanted T cells also maintained high levels of AcGFP expression, averaging 470% for all groups 1 week after transplantation (Table 3 ).
All the mice were killed 14 days after infusion and analyzed (Tables 2 and 3 ). Engraftment efficiency and AcGFP expression levels measured from mouse peripheral blood samples were even higher than that at day 7 (Tables 2 and 3 ). Large numbers of human cells were also detected in the mouse bone marrow, thymus and spleen (Table 2) . For all organs, no significant difference was seen in the levels of human CD3 þ T cells and AcGFP expression between the anti-CD3/anti-CD28 and the anti-CD3/FN-CH296 groups (Tables 2 and 3 ).
However, the infiltration of human cells into the bone marrow and thymus was significantly higher with the anti-CD3/FN-CH296 group than that with the anti-CD3 group. For instance, human cells were detected in the range of 70.1-96.0% in the thymus of anti-CD3/ FN-CH296 group, whereas they were in the range of 24.3-94.1% for the anti-CD3 group (Table 2) . Similar results were obtained when transgene expression levels were examined. With the anti-CD3/FN-CH296 group, AcGFP expression in human cells was 63, 64 and 73% in the bone marrow, thymus and spleen, respectively (Table 3) . In all cases, these values differed by less than 20% from that for PBMCs before injection (77.5%) (Tables 1 and 3 ). On the other hand, in the anti-CD3 group, AcGFP expression in human cells was approximately 50, 60 and 70% in the bone marrow, thymus and spleen, respectively (Table 3 ). In the bone marrow, the expression level decreased by almost 35% after injection (Tables 1 and 3 ).
The presence of human cells in the liver and gut was confirmed by immunohistochemical analysis. Human CD3 þ lymphocytes were observed in liver samples from all the transplanted mice (Figure 3a ). They were also observed in all gut sections from the anti-CD3/anti-CD28 and the anti-CD3/FN-CH296 groups (Figure 3a) . In the anti-CD3 group, however, these lymphocytes were observed in the gut sections of only two of five mice analyzed. Although the in vivo persistence of transduced T cells was observed for a short period, these results suggest that the in vivo persistence of genetically modified T cells Abbreviations: ND, not done; NOD/SCID, non-obese diabetic/severe combined immunodeficient; PBL, peripheral blood lymphocyte. The percentage of CD3+ cells are reported as mean and range (in parentheses). It is informative to compare the CD4 þ /CD8 þ ratio before and after transplantation. This ratio was 0.35 in anti-CD3-and anti-CD3/FN-CH296-stimulated cells before injection but was only 0.1 when the mice were killed (Figure 3b ). Although the ratio in the anti-CD3/ anti-CD28 group also fell substantially, the values before (0.83) and after (0.36) transplantation were still significantly higher than those in the other groups (Figure 3b) . These results indicate that stimulation by anti-CD3/FN-CH296 or anti-CD3 was preferable for the persistence of CD8 þ cells, whereas stimulation by anti-CD3/anti-CD28 was preferable for the persistence of CD4 þ cells in vivo and in vitro as well.
Discussion
In this work, we demonstrated that T-cell stimulation with FN-CH296 in combination with anti-CD3 allowed for efficient cell proliferation and a high level of transgene expression while preserving the naive phenotype of cell population, resulting in the efficient preservation of genetically modified T cells in vivo.
FN-CH296, immobilized on solid phase along with anti-CD3, delivers a stronger cell proliferation signal than anti-CD3 alone. Here, we demonstrate that the anti-CD3/ FN-CH296 stimulation method facilitates cell proliferation, resulting in T-cell expansion two-to fivefold greater than that observed with anti-CD3 stimulation alone in large-scale experiments. The strong cell growth was comparable to, or even higher than, that seen with cells stimulated with anti-CD3/anti-CD28. As FN-CH296 contains CS1 region, which can bind VLA-4 integrin molecules on T cells, these results are consistent with previous observations that FN promotes proliferation of T cells by signaling through the VLA-4 integrin molecules. [15] [16] [17] It is interesting to note that anti-CD3/FN-CH296 stimulation of the costimulatory molecule VLA-4 generates more cells with a naive phenotype than do other stimulation methods. One possible explanation is that VLA-4 binding to FN-CH296 selectively recruits naive cells into the cell cycle. It is not yet clear whether naive cells behave in a different manner from effector cells in response to VLA-4 costimulation or other stimulation. Experiments with sorted subpopulations would address this issue.
It has been reported that the subset of memory T cells is more susceptible than naive T cells to retrovirus-mediated gene transfer; however, studies have shown that the transduction efficiency of naive and memory T-cell populations is equivalent after two exposures to retrovirus. 25 Our results seem to support this observation. After two consecutive transductions, gene transfer efficiency into anti-CD3/FN-CH296-stimulated cells was sufficiently high; the expression of AcGFP from the One of the important issues for translating bench work to bedside is the feasibility of the scale-up process. We successfully established a scaled-up method for anti-CD3/FN-CH296 stimulation followed by retroviral gene transfer using three kinds of gas-permeable closed culture bags specially designed for this application. For instance, CultiLife 215 and CultiLife Eva bags are designed for large-scale culture of PBMCs. In particular, CultiLife 215 can be efficiently coated with anti-CD3 and FN-CH296, thereby allowing anti-CD3/FN-CH296 stimulation of PBMCs. To maximize retroviral transduction, retroviral supernatants were preloaded into FN-CH296-coated bags and subjected to centrifugation. The CultiLife Spin bag is designed to support efficient FN-CH296 coating and centrifugal force. Using this three-step bag transduction system, PBMCs expanded more than 50-fold during the 8-day culture period, reaching more than 10 9 cells easily. This suggests that the method is suitable for scale-up for clinical applications.
It has been proposed that terminally differentiated T cells with strong effector functions rapidly disappear after adoptive transfer, because they have exhausted their proliferative and survival capabilities. 2, 3 These data from human trials, along with data from mouse models, strongly support the hypothesis that less-differentiated T cells are more therapeutically effective upon adoptive transfer. This is likely due to their increased proliferative and survival potentials, their receptiveness to homeostatic and costimulatory signals, their homing to secondary lymphoid tissues and their ability to secrete IL-2. 8 According to the linear model of T-cell differentiation, antigen exposure controls the transition from naive to CM and eventually to effector memory cells. 26 In this respect, it is noticeable that anti-CD3/FN-CH296 and anti-CD3/anti-CD28 enriched different subsets of early stage of T lymphocytes; immobilized anti-CD3/ FN-CH296 enriched GFP þ lymphocytes with a CD45RA þ CCR7 þ naive phenotype, whereas activation by anti-CD3/anti-CD28 enriched GFP þ lymphocytes with a CD45RAÀCCR7 þ CM phenotype ( Figure 2 and Table 1 ). As transplanted animals were followed for only a short period, the long-term effects were not clear from this study. Nevertheless, the higher engraftment and GFP expression observed in several organs of animals in the anti-CD3/FN-CH296 and anti-CD3/anti-CD28 groups are probably due to their higher proportion of lessdifferentiated T cells compared with the anti-CD3 group.
Our results raise questions about the optimal subset of T lymphocytes for ATC transfer. Naive T cells have the potential to proliferate extensively on antigen encounter, but they are not generally thought to be useful for adoptive transfer, as they are unable to kill tumor cells. Although tumor-specific naive mouse T cells as well as early effector mouse T cells are effective for tumor treatment in vivo, 8 there is no clear evidence showing that tumor-specific naive human T cells are effective for adoptive transfer for the treatment of cancer. Using the different stimulation methods described in this study, it is possible to obtain human T lymphocytes enriched with naive, CM or effector cells. By transferring specific antitumor TCR genes to these different subsets of T lymphocytes, their anticancer effects could be compared in vivo as well as in vitro using an animal cancer model.
Stimulation with anti-CD3/FN-CH296 preferentially expands CD8 þ cells, whereas stimulation with anti-CD3/ anti-CD28 preferentially expands CD4 þ cells, consistent with previous reports by others 27 ( Figure 2 and Table 1 ). This tendency is maintained in vivo after transplantation (Figure 3b) . The effects of preferential proliferation of CD4 þ or CD8 þ cells on cancer or on the in vivo persistence of transduced T cells remain to be investigated.
It is generally agreed that one of the central issues for the development of clinical ATC transfer strategies is to produce adequate numbers of 'fit' cells. In this study, we introduced a novel T-cell stimulation and expansion method using FN-CH296. This method allows facilitated cell growth and efficient gene transfer while preserving naive phenotypes of T lymphocytes. The anticancer activity of FN-CH296-stimulated T cells using an in vivo cancer model and its underlying mechanisms still remain to be examined. This technology promises to be applicable to any kind of gene therapy protocols using adoptive T-cell immunotherapy. We expect that FN-CH296 costimulation of T cells mediated by VLA-4 ligation will open the door to the next generation of adoptive T-cell immunotherapies that can provide longlasting immune system reconstitution in patients.
